Table 2.
Survival rate of patients with colorectal neuroendocrine tumors in the ET group and SR group
| ET group | SR group | P-value | |
|---|---|---|---|
| Overall survival rate before PSM(%) | |||
| 1-year | 97.3 | 87.5 | < 0.001 |
| 3-year | 92.2 | 75.5 | < 0.001 |
| 5-year | 85.2 | 55.5 | < 0.001 |
| Overall survival rate after PSM(%) | |||
| 1-year | 97.1 | 88.6 | < 0.001 |
| 3-year | 89.6 | 77.6 | < 0.001 |
| 5-year | 77.4 | 57.5 | < 0.001 |
| Cancer specific survival rate before PSM(%) | |||
| 1-year | 99.5 | 93.5 | < 0.001 |
| 3-year | 98.8 | 88.0 | < 0.001 |
| 5-year | 97.9 | 77.3 | < 0.001 |
| Cancer specific survival rate after PSM(%) | |||
| 1-year | 99.3 | 94.4 | < 0.001 |
| 3-year | 98.2 | 89.8 | < 0.001 |
| 5-year | 96.5 | 80.2 | < 0.001 |
ET endoscopic therapy, SR surgical resection, PSM propensity score matching
Bold values indicate P < 0.05